Skip to main content
Signal8
Launch Terminal

Freenome, Inc. (FRNM)

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).

Sector: Services-Medical Laboratories

Industry: Medical - Diagnostics & Research

Freenome, Inc. logo

Freenome, Inc.

NASDAQ:FRNMHealthcare
-2.95%$12.48
AH$12.48+0.00%vs close
Mkt Cap$1.34B
Float49.59M
O/S107.45M
Vol
$ Vol
RVOL
Inst Own9.0%
SI9.0%
Earnings
Dilution
Freenome, Inc. logoNASDAQ:FRNM$12.48-2.95%
Phase Distribution
5 lead-sponsored trials·1 active·4 completed
Not applicable5
Status Overview
Recruiting1
Completed4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
  • Observational
    Completed

    AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

    -

    Colo-rectal Cancer, Cancer Colon +6

    Enrollment
    3,275
    Start
    Jan 2018
    Primary Completion
    Nov 2019
    Completion
    Nov 2019
    NCT03688906
  • Observational
    Completed

    Prevention of Colorectal Cancer Through Multiomics Blood Testing

    Freenome test

    Colon Cancer, Rectal Cancer +9

    Enrollment
    48,995
    Start
    May 2020
    Primary Completion
    Feb 2024
    Completion
    Feb 2024
    NCT04369053
  • Observational
    Completed

    The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

    Freenome Test

    Cancer

    Enrollment
    7,435
    Start
    Feb 2022
    Primary Completion
    Jul 2024
    Completion
    Jul 2025
    NCT05254834
  • Observational
    Completed

    The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening

    Freenome Test

    Newly-diagnosed Cancers, Non-cancer Controls

    Enrollment
    788
    Start
    Sep 2022
    Primary Completion
    Dec 2023
    Completion
    May 2024
    NCT05516927
  • Observational
    Recruiting

    Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

    blood draw

    Lung Cancer Diagnosis

    Enrollment
    20,000
    Start
    Nov 2023
    Primary Completion
    Jun 2026est.
    Completion
    Jun 2027est.
    NCT06122077
Search ClinicalTrials.gov for “Freenome”